Oncternal Therapeutics (NASDAQ:ONCT – Get Free Report)‘s stock had its “market perform” rating reaffirmed by equities researchers at Northland Securities in a report released on Thursday, Benzinga reports. They currently have a $2.00 price objective on the stock. Northland Securities’ target price would indicate a potential upside of 36.99% from the company’s current price.
Other analysts have also recently issued reports about the stock. StockNews.com assumed coverage on shares of Oncternal Therapeutics in a report on Sunday, September 8th. They set a “hold” rating for the company. HC Wainwright decreased their target price on shares of Oncternal Therapeutics from $19.00 to $18.00 and set a “buy” rating for the company in a research note on Monday, August 12th. Finally, Brookline Capital Management restated a “hold” rating on shares of Oncternal Therapeutics in a report on Thursday.
Check Out Our Latest Stock Analysis on Oncternal Therapeutics
Oncternal Therapeutics Stock Down 14.1 %
Oncternal Therapeutics (NASDAQ:ONCT – Get Free Report) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($2.89) earnings per share for the quarter, beating the consensus estimate of ($3.03) by $0.14. Oncternal Therapeutics had a negative return on equity of 136.10% and a negative net margin of 1,948.70%. The firm had revenue of $0.80 million for the quarter, compared to analyst estimates of $0.24 million. During the same period in the previous year, the firm earned ($3.00) earnings per share. Equities research analysts anticipate that Oncternal Therapeutics will post -11.4 earnings per share for the current year.
Institutional Trading of Oncternal Therapeutics
An institutional investor recently bought a new position in Oncternal Therapeutics stock. Pasadena Private Wealth LLC purchased a new stake in shares of Oncternal Therapeutics, Inc. (NASDAQ:ONCT – Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 25,000 shares of the company’s stock, valued at approximately $190,000. Pasadena Private Wealth LLC owned approximately 0.84% of Oncternal Therapeutics at the end of the most recent quarter. 16.05% of the stock is owned by institutional investors.
About Oncternal Therapeutics
Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.
Featured Articles
- Five stocks we like better than Oncternal Therapeutics
- How to buy stock: A step-by-step guide for beginners
- Powering Your Portfolio: The Utility Sector’s Electrifying Surge
- Insider Trades May Not Tell You What You Think
- Adobe Stock Builds Long-Term Value: Consider Buying on the Dip
- What Are Dividend Champions? How to Invest in the Champions
- Albemarle Jumps as Lithium Stock Buying Frenzy Takes Off
Receive News & Ratings for Oncternal Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncternal Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.